Pharmaceutically leveraging abnormally activated PI3K pathway could inhibit tumor growth and boost anti-tumor immune responses by facilitating immune infiltration or blocking the effects of immunosuppressive cells (Okkenhaug et al, 2016; Sun et al, 2021). Here, PIK3CA is linked to neoplasm.